false
Catalog
2024 World Conference on Lung Cancer (WCLC) - Post ...
P2.07C.03 Limited Efficacy of Immunochemotherapy i ...
P2.07C.03 Limited Efficacy of Immunochemotherapy in Pulmonary Invasive Mucinous Adenocarcinoma and Mucoepidermoid Carcinoma as Neoadjuvant Setting
Back to course
Pdf Summary
This study investigated the effectiveness of adding immune checkpoint inhibitors (ICIs) to chemotherapy as a neoadjuvant treatment for invasive mucinous adenocarcinoma (IMA) and mucoepidermoid carcinoma (MEC) of the lung. The focus was on determining the specific efficacy of this immunochemotherapy regimen in managing these two rare types of lung cancer characterized by mucinous cells.<br /><br />A retrospective analysis was conducted on 14 patients (12 with IMA and 2 with MEC) treated at Guangdong Provincial People’s Hospital and Cancer Hospital Chinese Academy of Medical Sciences. The majority of these patients (92.9%) achieved R0 resection after 2 to 4 cycles of neoadjuvant chemoimmunotherapy. Genetic mutations noted included KRAS, HER2, and RET, with no EGFR or ALK mutations detected. PD-L1 expression was low, with most cases showing a tumor proportion score (TPS) of 0 or 1%.<br /><br />Outcomes indicated that only one patient displayed a partial radiological response, with the others maintaining stable disease. However, no major pathological response (MPR) or pathological complete response (pCR) was observed. Over a median follow-up period of 19.6 months, five patients experienced postoperative recurrence or metastasis, with intrapulmonary metastases being the primary location of relapse. The median event-free survival (EFS) was documented at 16 months.<br /><br />In conclusion, the study found limited efficacy of chemoimmunotherapy in the neoadjuvant treatment of IMA and MEC, with minimal therapeutic response and recurrence observed. Further studies with larger cohorts are necessary to validate these findings and explore potentially more effective therapeutic strategies.
Asset Subtitle
Zhen-bin Qiu
Meta Tag
Speaker
Zhen-bin Qiu
Topic
Early-Stage NSCLC
Keywords
immune checkpoint inhibitors
neoadjuvant treatment
invasive mucinous adenocarcinoma
mucoepidermoid carcinoma
lung cancer
chemoimmunotherapy
R0 resection
genetic mutations
PD-L1 expression
event-free survival
×
Please select your language
1
English